Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback